Italia markets close in 36 minutes
FTSE MIB
33.542,32 -164,89 (-0,49%) Dow Jones
39.014,93 -97,23 (-0,25%) Nasdaq
17.759,29 +41,63 (+0,23%) Nikkei 225
39.667,07 +493,92 (+1,26%) Petrolio
80,41 -0,42 (-0,52%) Bitcoin EUR
57.829,22 +71,92 (+0,12%)
NBIX Jul 2024 125.000 put
OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
In data: 02:42PM EDT. Mercato aperto.
| Chiusura precedente | 1,0000 |
| Aperto | 0,8900 |
| Denaro | 1,0000 |
| Domanda | 1,3500 |
| Prezzo d'esercizio | 125,00 |
| Scadenza | 2024-07-19 |
| Min-Max giorno | 0,8900 - 0,9500 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 299 |
GlobeNewswireSosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational treat
© 2024 Yahoo. Tutti i diritti riservati.